Last reviewed · How we verify
Double Blind Esomeprazole
Esomeprazole is a proton pump inhibitor that suppresses gastric acid secretion by blocking the H+/K+-ATPase enzyme in the stomach's parietal cells.
Esomeprazole is a proton pump inhibitor that suppresses gastric acid secretion by blocking the H+/K+-ATPase enzyme in the stomach's parietal cells. Used for Gastroesophageal reflux disease (GERD), Peptic ulcer disease, Zollinger-Ellison syndrome.
At a glance
| Generic name | Double Blind Esomeprazole |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | Proton pump inhibitor (PPI) |
| Target | H+/K+-ATPase (proton pump) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | Phase 3 |
Mechanism of action
Esomeprazole is the active S-enantiomer of omeprazole. It irreversibly inhibits the proton pump (H+/K+-ATPase) on the secretory surface of gastric parietal cells, reducing both basal and stimulated gastric acid production. This mechanism provides rapid and sustained acid suppression, making it effective for treating acid-related gastrointestinal disorders.
Approved indications
- Gastroesophageal reflux disease (GERD)
- Peptic ulcer disease
- Zollinger-Ellison syndrome
- Prevention of NSAID-induced ulcers
Common side effects
- Headache
- Diarrhea
- Nausea
- Abdominal pain
- Constipation
- Flatulence
Key clinical trials
- Efficacy of Clostridium Butyricum in Alleviating Anxiety and Depression in Patients With Functional Dyspepsia (PHASE4)
- Efficacy of Bacillus Coagulans in Alleviating Anxiety and Depression in Patients With Functional Dyspepsia (PHASE4)
- Heartburn, Gastroesophageal Reflux Disease (PHASE4)
- A Study to Test Bioavailability of of 2 New Formulations of UCB0599 in Healthy Participants in Part A and to Test Safety, Tolerability, and Pharmacokinetic (PK) of UCB0599 in Healthy Japanese and Chinese Participants in Part B (PHASE1)
- A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of INCB160058 When Administered Orally to Healthy Adult Participant (PHASE1)
- Stop of Proton-pump Inhibitor Treatment in Patients With Liver Cirrhosis - a Double-blind, Placebo-controlled Trial (PHASE4)
- A Phase III Clinical Trial for Efficacy and Safety Evaluation of JP-1366 Tablets on Reflux Esophagitis (PHASE3)
- Phase II Clinical Study of Vonorasan Fumarate Injection in the Treatment of Peptic Ulcer Bleeding (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Double Blind Esomeprazole CI brief — competitive landscape report
- Double Blind Esomeprazole updates RSS · CI watch RSS
- AstraZeneca portfolio CI